Mayne Pharma Challenges Cosette’s Termination Notice, Urges Shareholder Support

The latest announcement is out from Mayne Pharma Group ( (AU:MYX) ).

Mayne Pharma has received another purported termination notice from Cosette Pharmaceuticals regarding their scheme implementation deed, which Mayne Pharma intends to reject as invalid. The company is proceeding with its planned Scheme Meeting and encourages shareholders to vote in favor of the Scheme Resolution, maintaining its stance that there is no lawful basis for Cosette’s termination attempt.

The most recent analyst rating on (AU:MYX) stock is a Buy with a A$7.09 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.

More about Mayne Pharma Group

Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, particularly in dermatology and women’s health in the United States. The company also offers contract development and manufacturing services globally and has a 40-year track record in developing innovative oral drug delivery systems.

Average Trading Volume: 978,435

Technical Sentiment Signal: Sell

Current Market Cap: A$429.8M

See more data about MYX stock on TipRanks’ Stock Analysis page.